CYIOS Corp. appoints John O'Shea as CEO and Chairman to drive AI-led growth and targeted acquisitions
Melbourne, Australia and Palm Beach, Fla. - Dec. 2, 2025 - CYIOS Corp. (OTC: CYIO) has named John O'Shea as Chief Executive Officer and Chairman of the Board. The mandate is clear: professionalize operations, expand the medical footprint, and build an AI-enabled operating model that compounds value over the next 24-36 months.
O'Shea is a serial entrepreneur and senior operator with more than 30 years across finance, technology, education, and venture building. His focus at CYIOS: sharpen execution, deploy AI for efficiency and growth, and pursue strategic acquisitions that strengthen vertical integration within the medical sector.
Why this move matters to executives
- Unified thesis: combine medical supply scale with AI/SaaS leverage for margin and speed.
- Clear growth levers: operational transparency, disciplined M&A, and a commercial AI product line.
- Time-bound roadmap: 24-36 months focused on integration, distribution expansion, and product breadth across the U.S. and the Caribbean.
A leader with multi-sector execution
O'Shea brings a breadth of experience across banking, fintech, SaaS, and advisory-built on turning strategy into measurable results.
- Senior Executive roles at Bendigo Bank and Adelaide Bank, driving growth, product innovation, and efficiency.
- Founder & CEO of INCH Corp Pty Ltd, scaling tech-enabled finance and advisory solutions.
- Head of Marketing & Sales at Hannon Insurance & Superannuation, leading national growth initiatives.
- Senior Advisor, Sales & Business Development at William M. Mercer, serving enterprise clients across Australia.
- Founder of Helio Lending, an early entrant in digital-asset lending.
- Built education platforms in collaboration with RMIT University, including nationally adopted sustainability and learning programs.
His career is defined by restructuring complex orgs, aligning teams, and executing at speed.
AI as an operating system: CyioIQ
Under O'Shea, CYIOS is planning CyioIQ-a next-gen AI/SaaS platform aimed at streamlining operations for Noir Medical Supplies. The goal: automate the operational backbone and turn those capabilities into a commercial product.
- Procurement: smarter sourcing and stock optimization.
- Pricing: dynamic pricing aligned to market and margin goals.
- Order flow: faster, cleaner fulfillment from quote to delivery.
- Customer management: improved retention and service quality.
- Analytics: real-time dashboards for decisions that move the needle.
This dual-use approach-internal efficiency and external revenue-positions CYIOS to participate in the growing digital health automation market.
Acquisitions and JVs: built for scale
Early discussions are underway with acquisition candidates and JV partners chosen to strengthen vertical integration, expand product lines, and widen distribution in the U.S. and the Caribbean. This M&A strategy is designed to pair operational gains from AI with durable distribution advantages.
Expect focus on businesses that add supply chain resilience, category depth, and margin expansion.
Operating discipline and governance
O'Shea has already influenced the Company's shift toward stronger governance, financial clarity, and consistent reporting. The management team is aligned with shareholder interests and committed to clear, frequent communication as milestones are met.
What to watch next
- Progress updates on CyioIQ and its deployment within Noir Medical Supplies.
- Announcements on acquisitions and JV structures that extend distribution and product coverage.
- Operational KPIs tied to efficiency, margin, and revenue diversification.
"This is a transformative moment for CYIOS," said O'Shea. "The Company has a powerful foundation, a growing footprint in the medical supply chain, and significant untapped opportunity across AI, SaaS, and strategic acquisitions. I am energized to lead our talented team as we strengthen operations, expand into new markets, and unlock the full value of our business portfolio."
About CYIOS Corp.
CYIOS Corp. is a diversified holding company focused on acquiring and operating high-growth businesses with an emphasis on medical supplies, AI/SaaS development, and strategic innovation. Through its subsidiary, Noir Medical Supplies, CYIOS provides high-quality products to healthcare providers across the United States and the Caribbean. The Company is expanding through technology innovation, operational excellence, and data-driven growth strategies.
Forward-looking statement
This release includes forward-looking statements that involve risks and uncertainties, including those related to development timelines, commercialization, funding, competition, collaborations, management continuity, intellectual property, privacy and security compliance, and regulatory actions. Actual results may differ materially. CYIOS undertakes no obligation to update forward-looking statements except as required by law.
Media & Investor Relations
David Kugelman
Atlanta Capital Partners, LLC
(866) 692-6847 (U.S. & Canada Toll-Free)
(404) 281-8556 (Mobile / WhatsApp)
dk@atlcp.com
If you're building executive-level AI fluency to support initiatives like CyioIQ, explore curated programs by job role here: AI courses by job.
Your membership also unlocks:
